American Journal of Cardiology
Volume 103, Issue 8 , Pages 1107-1112 , 15 April 2009

Combination Antiplatelet Therapy for Secondary Stroke Prevention: Enhanced Efficacy or Double Trouble?

  • M. Haris U. Usman, MD

      Affiliations

    • Lankenau Institute for Medical Research, Wynnewood, Pennsylvania
    • Mercy Catholic Medical Center, Drexel University College of Medicine, Darby, Pennsylvania
    • ,
  • Lawrence A. Notaro, MD

      Affiliations

    • Lankenau Institute for Medical Research, Wynnewood, Pennsylvania
    • ,
  • Rangadham Nagarakanti, MD

      Affiliations

    • Lankenau Institute for Medical Research, Wynnewood, Pennsylvania
    • ,
  • Eric Brahin, MD

      Affiliations

    • Department of Neurology, Drexel University, Philadelphia, Pennsylvania
    • ,
  • Scott Dessain, MD, PhD

      Affiliations

    • Lankenau Institute for Medical Research, Wynnewood, Pennsylvania
    • Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
    • ,
  • Edward Gracely, PhD

      Affiliations

    • Department of Epidemiology and Biostatistics, Drexel University, Philadelphia, Pennsylvania
    • ,
  • Michael D. Ezekowitz, MBChB, DPhil

      Affiliations

    • Lankenau Institute for Medical Research, Wynnewood, Pennsylvania
    • Corresponding Author InformationCorresponding author: Tel: 610-645-3343; fax: 610-645-3471

Received 8 October 2008 ,Revised 5 January 2009 ,Accepted 5 January 2009.

References 

  1. Mueller RL, Scheidt S. History of drugs for thrombotic disease (Discovery, development, and directions for the future). Circulation. 1994;89:432–449
  2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106
  3. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:630S–669S
  4. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–782
  5. Boysen G. Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. J Intern Med. 1999;246:239–245
  6. Serebruany VL, Malinin AI, Eisert RM, Sane DC. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004;75:40–47
  7. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95:1218–1222
  8. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444–1451
  9. The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345–1349
  10. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–1912
  11. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet. 1996;348:1329–1339
  12. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352:1305–1316
  13. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331–337
  14. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044–1054
  15. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717
  16. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study (2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke). J Neurol Sci. 1996;143:1–13
  17. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325:1261–1266
  18. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007;6:115–124
  19. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665–1673
  20. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238–1251
  21. Tong DC, Adami A, Moseley ME, Marks MP. Prediction of hemorrhagic transformation following acute stroke: role of diffusion- and perfusion-weighted magnetic resonance imaging. Arch Neurol. 2001;58:587–593
  22. Boulanger JM, Coutts SB, Eliasziw M, Gagnon AJ, Simon JE, Subramaniam S, et al. Cerebral microhemorrhages predict new disabling or fatal strokes in patients with acute ischemic stroke or transient ischemic attack. Stroke. 2006;37:911–914
  23. Dalen JE. Aspirin to prevent heart attack and stroke: what's the right dose?. Am J Med. 2006;119:198–202
  24. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297:2018–2024
  25. Hanley SP, Bevan J, Cockbill SR, Heptinstall S. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet. 1981;1:969–971
  26. Montalescot G, Maclouf J, Drobinski G, Salloum J, Grosgogeat Y, Thomas D. Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin. J Am Coll Cardiol. 1994;24:33–38
  27. Forster W, Parratt JR. The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low?. Cardiovasc Drugs Ther. 1997;10:727–734
  28. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999;100:1667–1672
  29. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533
  30. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
  31. Aktas B, Utz A, Hoenig-Liedl P, Walter U, Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke. 2003;34:764–769
  32. Lenz TL, Hilleman DE. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother. 2000;34:1283–1290
  33. Radomski MW, Rees DD, Dutra A, Moncada S. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol. 1992;107:745–749
  34. Garg UC, Hassid A. Nitric oxide–generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774–1777
  35. Tsao PS, Buitrago R, Chan JR, Cooke JP. Fluid flow inhibits endothelial adhesiveness (Nitric oxide and transcriptional regulation of VCAM-1). Circulation. 1996;94:1682–1689
  36. Serebruany VL, Malinin AI, Ferguson JJ, Vahabi J, Atar D, Hennekens CH. Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol. 2008;22:315–321
  37. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis In Myocardial Infarction (TIMI) trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1–11
  38. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682
  39. Serebruany VL, Atar D. Assessment of bleeding events in clinical trials—proposal of a new classification. Am J Cardiol. 2007;99:288–290

PII: S0002-9149(09)00033-2

doi: 10.1016/j.amjcard.2009.01.003

American Journal of Cardiology
Volume 103, Issue 8 , Pages 1107-1112 , 15 April 2009

Article Tools

* Image Usage & Resolution